Symbols / ORIC Stock $9.44 -2.18% ORIC Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
ORIC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jacob M. Chacko M.B.A., M.D.
Exch · Country NMS · United States
Market Cap 1.06B
Enterprise Value 694.41M
Income -129.47M
Sales —
FCF (ttm) -69.10M
Book/sh 3.90
Cash/sh 2.81
Employees 104
Insider 10d —
IPO Apr 24, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.10
PEG —
P/S —
P/B 2.42
P/C —
EV/EBITDA -4.90
EV/Sales —
Quick Ratio 13.79
Current Ratio 14.13
Debt/Eq 1.94
LT Debt/Eq —
EPS (ttm) -1.47
EPS next Y -1.55
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-04
Earnings (prior) 2026-02-23
ROA -26.17%
ROE -41.27%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 112.01M
Shs Float 67.57M
Insider Own 6.51%
Instit Own 117.92%
Short Float 18.72%
Short Ratio 8.21
Short Interest 20.74M
52W High 14.93
vs 52W High -36.77%
52W Low 4.52
vs 52W Low 108.85%
Beta 1.36
Impl. Vol. 3.14%
Rel Volume 0.70
Avg Volume 1.90M
Volume 1.33M
Target (mean) $21.00
Tgt Median $22.00
Tgt Low $15.00
Tgt High $25.00
# Analysts 13
Recom None
Prev Close $9.65
Price $9.44
Change -2.18%
About

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$21.00
Mean price target
2. Current target
$9.44
Latest analyst target
3. DCF / Fair value
$-11.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.44
Low
$15.00
High
$25.00
Mean
$21.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-02 reit HC Wainwright & Co. Buy → Buy $25
2026-04-01 main Wedbush Outperform → Outperform $17
2026-03-13 reit HC Wainwright & Co. Buy → Buy $25
2026-02-24 main Citigroup Buy → Buy $17
2026-02-24 main HC Wainwright & Co. Buy → Buy $25
2026-02-24 reit Wedbush Outperform → Outperform $20
2026-01-13 reit Wedbush Outperform → Outperform $20
2026-01-07 init Piper Sandler — → Overweight $22
2025-12-08 main Wells Fargo Overweight → Overweight $25
2025-12-08 reit Wedbush Outperform → Outperform $20
2025-11-20 init Evercore ISI Group — → Outperform $25
2025-11-18 init Wolfe Research — → Peer Perform —
2025-11-18 main JP Morgan Overweight → Overweight $20
2025-11-17 main Citigroup Buy → Buy $16
2025-11-14 main HC Wainwright & Co. Buy → Buy $23
2025-11-14 main Wells Fargo Overweight → Overweight $19
2025-11-14 main Oppenheimer Outperform → Outperform $15
2025-08-14 main JP Morgan Overweight → Overweight $17
2025-08-14 main HC Wainwright & Co. Buy → Buy $19
2025-08-13 reit Guggenheim Buy → Buy $18
News
RSS: Latest ORIC news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-24 PISCITELLI DOMINIC G. Chief Financial Officer — 52,000 $13.51 $702,686
2026-02-24 PISCITELLI DOMINIC G. Chief Financial Officer — 52,000 $4.36 $226,720
2026-01-16 HEYMAN RICHARD A Director — 6,700 $12.00 $80,431
2025-12-16 CHACKO JACOB M Chief Executive Officer — 33,374 $9.06 $302,368
2025-12-16 PISCITELLI DOMINIC G. Chief Financial Officer — 10,720 $9.06 $97,127
2025-12-16 MULTANI PRATIK S Officer — 10,720 $9.06 $97,129
2025-12-15 MULTANI PRATIK S Officer — 29,333 — —
2025-12-15 CHACKO JACOB M Chief Executive Officer — 83,666 — —
2025-12-15 PISCITELLI DOMINIC G. Chief Financial Officer — 29,333 — —
2025-12-08 KUNKEL LORI ANNE Director — 10,000 $7.90 $79,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
143.00
+0.08%
142.90
+28.99%
110.78
+27.68%
86.77
Research And Development
109.82
-3.73%
114.07
+33.93%
85.17
+38.09%
61.68
Selling General And Administration
33.19
+15.14%
28.82
+12.55%
25.61
+2.08%
25.09
General And Administrative Expense
33.19
+15.14%
28.82
+12.55%
25.61
+2.08%
25.09
Other Gand A
33.19
+15.14%
28.82
+12.55%
25.61
+2.08%
25.09
Total Expenses
143.00
+0.08%
142.90
+28.99%
110.78
+27.68%
86.77
Operating Income
-143.00
-0.08%
-142.90
-28.99%
-110.78
-27.68%
-86.77
Total Operating Income As Reported
-143.00
-0.08%
-142.90
-28.99%
-110.78
-20.72%
-91.77
EBITDA
-141.78
+0.00%
-141.79
-29.19%
-109.75
-27.91%
-85.80
Normalized EBITDA
-141.78
+0.00%
-141.79
-29.19%
-109.75
-35.83%
-80.80
Reconciled Depreciation
1.22
+10.21%
1.11
+7.27%
1.03
+6.83%
0.97
EBIT
-143.00
-0.08%
-142.90
-28.99%
-110.78
-27.68%
-86.77
Total Unusual Items
—
—
0.00
+100.00%
-5.00
Total Unusual Items Excluding Goodwill
—
—
0.00
+100.00%
-5.00
Special Income Charges
—
—
0.00
+100.00%
-5.00
Other Special Charges
—
—
—
5.00
Net Income
-129.47
-1.27%
-127.85
-26.96%
-100.70
-12.99%
-89.12
Pretax Income
-129.47
-1.27%
-127.85
-26.96%
-100.70
-12.99%
-89.12
Net Non Operating Interest Income Expense
—
—
—
2.65
Net Interest Income
—
—
—
2.65
Interest Income Non Operating
—
—
—
2.65
Interest Income
—
—
—
2.65
Other Income Expense
13.54
-10.05%
15.05
+49.24%
10.08
+528.15%
-2.35
Other Non Operating Income Expenses
13.54
-10.05%
15.05
+49.24%
10.08
+281.21%
2.65
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-129.47
-1.27%
-127.85
-26.96%
-100.70
-12.99%
-89.12
Net Income From Continuing Operation Net Minority Interest
-129.47
-1.27%
-127.85
-26.96%
-100.70
-12.99%
-89.12
Net Income From Continuing And Discontinued Operation
-129.47
-1.27%
-127.85
-26.96%
-100.70
-12.99%
-89.12
Net Income Continuous Operations
-129.47
-1.27%
-127.85
-26.96%
-100.70
-12.99%
-89.12
Normalized Income
-129.47
-1.27%
-127.85
-26.96%
-100.70
-19.70%
-84.12
Net Income Common Stockholders
-129.47
-1.27%
-127.85
-26.96%
-100.70
-12.99%
-89.12
Diluted EPS
—
-1.83
+6.63%
-1.96
+12.89%
-2.25
Basic EPS
—
-1.83
+6.63%
-1.96
+12.89%
-2.25
Basic Average Shares
—
69.73
+35.52%
51.45
+29.75%
39.66
Diluted Average Shares
—
69.73
+35.52%
51.45
+29.75%
39.66
Diluted NI Availto Com Stockholders
-129.47
-1.27%
-127.85
-26.96%
-100.70
-12.99%
-89.12
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
408.89
+49.15%
274.14
+8.78%
252.01
+1.95%
247.18
Current Assets
288.47
+10.00%
262.25
+23.36%
212.60
+1.02%
210.46
Cash Cash Equivalents And Short Term Investments
281.49
+9.97%
255.96
+22.95%
208.19
+0.93%
206.27
Cash And Cash Equivalents
45.67
-23.12%
59.41
+154.05%
23.38
-65.01%
66.84
Other Short Term Investments
235.82
+19.98%
196.55
+6.36%
184.80
+32.54%
139.43
Prepaid Assets
—
—
—
—
Other Current Assets
6.98
+10.94%
6.29
+42.63%
4.41
+5.38%
4.18
Total Non Current Assets
120.42
+912.65%
11.89
-69.82%
39.41
+7.32%
36.72
Net PPE
2.42
-17.41%
2.92
+2.17%
2.86
-12.02%
3.25
Gross PPE
10.07
-3.21%
10.40
+11.16%
9.36
+3.43%
9.05
Accumulated Depreciation
-7.65
-2.34%
-7.48
-15.12%
-6.49
-12.10%
-5.79
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.99
+1.85%
0.97
+22.45%
0.79
-3.17%
0.82
Other Properties
7.01
-5.06%
7.39
+11.98%
6.60
+5.55%
6.25
Leases
2.06
+1.08%
2.04
+3.86%
1.97
-0.56%
1.98
Investments And Advances
110.76
0.00
-100.00%
26.85
+22.33%
21.95
Other Non Current Assets
7.25
-19.19%
8.97
-7.51%
9.70
-15.81%
11.52
Total Liabilities Net Minority Interest
24.53
-20.93%
31.02
+11.11%
27.92
+12.45%
24.83
Current Liabilities
20.42
-17.83%
24.85
+21.45%
20.46
+32.95%
15.39
Payables And Accrued Expenses
8.99
-35.83%
14.02
+25.39%
11.18
+50.82%
7.41
Payables
3.82
+147.03%
1.55
+63.98%
0.94
-28.48%
1.32
Accounts Payable
3.82
+147.03%
1.55
+63.98%
0.94
-28.48%
1.32
Current Accrued Expenses
5.17
-58.54%
12.47
+21.83%
10.23
+68.00%
6.09
Pensionand Other Post Retirement Benefit Plans Current
8.09
+5.83%
7.65
+17.14%
6.53
+22.77%
5.32
Current Debt And Capital Lease Obligation
3.33
+4.62%
3.18
+15.66%
2.75
+3.50%
2.66
Current Capital Lease Obligation
3.33
+4.62%
3.18
+15.66%
2.75
+3.50%
2.66
Current Deferred Liabilities
—
—
—
—
Total Non Current Liabilities Net Minority Interest
4.11
-33.41%
6.17
-17.25%
7.46
-20.96%
9.44
Other Non Current Liabilities
4.11
-33.41%
6.17
-17.25%
7.46
-20.96%
9.44
Stockholders Equity
384.36
+58.09%
243.12
+8.49%
224.09
+0.78%
222.35
Common Stock Equity
384.36
+58.09%
243.12
+8.49%
224.09
+0.78%
222.35
Capital Stock
0.01
+57.14%
0.01
+16.67%
0.01
+20.00%
0.01
Common Stock
0.01
+57.14%
0.01
+16.67%
0.01
+20.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
98.53
+38.73%
71.02
+29.45%
54.87
+21.68%
45.09
Ordinary Shares Number
98.53
+38.73%
71.02
+29.45%
54.87
+21.68%
45.09
Additional Paid In Capital
1,075.81
+33.56%
805.51
+22.28%
658.75
+18.08%
557.87
Retained Earnings
-692.24
-23.01%
-562.77
-29.40%
-434.93
-30.13%
-334.23
Gains Losses Not Affecting Retained Earnings
0.79
+107.39%
0.38
+46.90%
0.26
+119.98%
-1.29
Other Equity Adjustments
0.79
+107.39%
0.38
+46.90%
0.26
+119.98%
-1.29
Total Equity Gross Minority Interest
384.36
+58.09%
243.12
+8.49%
224.09
+0.78%
222.35
Total Capitalization
384.36
+58.09%
243.12
+8.49%
224.09
+0.78%
222.35
Working Capital
268.05
+12.91%
237.40
+23.56%
192.14
-1.50%
195.07
Invested Capital
384.36
+58.09%
243.12
+8.49%
224.09
+0.78%
222.35
Total Debt
3.33
+4.62%
3.18
+15.66%
2.75
+3.50%
2.66
Capital Lease Obligations
3.33
+4.62%
3.18
+15.66%
2.75
+3.50%
2.66
Net Tangible Assets
384.36
+58.09%
243.12
+8.49%
224.09
+0.78%
222.35
Tangible Book Value
384.36
+58.09%
243.12
+8.49%
224.09
+0.78%
222.35
Available For Sale Securities
110.76
—
26.85
+22.33%
21.95
Investmentin Financial Assets
110.76
0.00
-100.00%
26.85
+22.33%
21.95
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-110.97
+1.50%
-112.66
-31.48%
-85.69
-14.03%
-75.14
Cash Flow From Continuing Operating Activities
-110.97
+1.50%
-112.66
-31.48%
-85.69
-14.03%
-75.14
Net Income From Continuing Operations
-129.47
-1.27%
-127.85
-26.96%
-100.70
-12.99%
-89.12
Depreciation Amortization Depletion
1.22
+10.21%
1.11
+7.27%
1.03
+6.83%
0.97
Depreciation
1.22
+10.21%
1.11
+7.27%
1.03
+6.83%
0.97
Depreciation And Amortization
1.22
+10.21%
1.11
+7.27%
1.03
+6.83%
0.97
Stock Based Compensation
25.04
+23.87%
20.21
+32.75%
15.23
+5.30%
14.46
Operating Gains Losses
—
—
0.02
-45.00%
0.04
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.02
-45.00%
0.04
Change In Working Capital
-5.46
-377.39%
1.97
-59.82%
4.90
+1200.67%
-0.45
Change In Prepaid Assets
1.79
+1149.65%
0.14
-91.17%
1.62
+57.28%
1.03
Change In Payables And Accrued Expense
-7.25
-497.04%
1.82
-44.33%
3.28
+322.24%
-1.48
Change In Payable
—
—
—
—
Change In Account Payable
—
—
—
—
Investing Cash Flow
-148.03
-768.70%
22.14
+151.00%
-43.40
+60.27%
-109.25
Cash Flow From Continuing Investing Activities
-148.03
-768.70%
22.14
+151.00%
-43.40
+60.27%
-109.25
Net PPE Purchase And Sale
-0.71
+40.07%
-1.19
-39.93%
-0.85
+59.14%
-2.08
Purchase Of PPE
-0.71
+40.07%
-1.19
-39.93%
-0.85
+59.14%
-2.08
Capital Expenditure
-0.71
+40.07%
-1.19
-39.93%
-0.85
+59.14%
-2.08
Net Investment Purchase And Sale
-147.32
-731.59%
23.32
+154.81%
-42.55
+60.29%
-107.17
Purchase Of Investment
-399.82
-58.71%
-251.92
-5.30%
-239.24
-0.47%
-238.12
Sale Of Investment
252.50
-8.26%
275.25
+39.94%
196.69
+50.20%
130.95
Financing Cash Flow
245.26
+93.81%
126.55
+47.74%
85.66
+239.58%
25.23
Cash Flow From Continuing Financing Activities
245.26
+93.81%
126.55
+47.74%
85.66
+239.58%
25.23
Net Common Stock Issuance
244.37
+95.50%
125.00
+47.06%
85.00
+240.00%
25.00
Proceeds From Stock Option Exercised
3.29
+91.95%
1.72
+93.79%
0.89
+41.83%
0.62
Net Other Financing Charges
-2.40
-1326.79%
-0.17
+25.99%
-0.23
+43.11%
-0.40
Changes In Cash
-13.74
-138.14%
36.02
+182.94%
-43.43
+72.71%
-159.17
Beginning Cash Position
59.90
+150.88%
23.88
-64.53%
67.31
-70.28%
226.47
End Cash Position
46.16
-22.93%
59.90
+150.88%
23.88
-64.53%
67.31
Free Cash Flow
-111.68
+1.90%
-113.85
-31.56%
-86.54
-12.06%
-77.22
Amortization Of Securities
-2.30
+71.62%
-8.10
-31.35%
-6.17
-492.03%
-1.04
Common Stock Issuance
244.37
+95.50%
125.00
+47.06%
85.00
+240.00%
25.00
Issuance Of Capital Stock
244.37
+95.50%
125.00
+47.06%
85.00
+240.00%
25.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category